Physician profile
Nisha Panday
NPI 1124484399
$4,313.47
in general payments reported to CMS, 2019-2025
28 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,575 · 2022: $1,261 · 2023: $934 · 2024: $280 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $691.61 | 2021-2024 | |
| Amgen INC. | $465.49 | 2021-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $422.17 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.49 | 2021-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $379.35 | 2021-2024 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $298.19 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $284.37 | 2021-2023 | Xarelto |
| Boston Scientific Corporation | $213.32 | 2021-2025 | Watchman Access System, Cds - Mct/Cem Monitoring |
| Bayer Healthcare Pharmaceuticals INC. | $162.93 | 2021-2025 | |
| Novo Nordisk INC | $160.79 | 2021-2025 | Ozempic |
| Pfizer INC. | $150.40 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $85.53 | 2021-2024 | Onpattro |
| Philips North America LLC | $70.16 | 2023 | |
| Impulse Dynamics (USA) INC. | $65.48 | 2023 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $60.90 | 2024 | Brilinta, Farxiga, Wainua |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $57.95 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $48.14 | 2021 | |
| Esperion Therapeutics, INC. | $43.73 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.52 | 2021-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $31.50 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $25.55 | 2024 | Arcalyst |
| Abbott Laboratories | $24.82 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.70 | 2024 | Lifevest |
| Bridgebio Pharma, INC. | $20.80 | 2025 | Attruby |
| Scpharmaceuticals INC. | $20.65 | 2025 | |
| Glaxosmithkline, LLC. | $17.54 | 2025 | Arexvy, Shingrix |
| Chiesi USA, INC. | $13.87 | 2023 | Kengreal, Cleviprex |
| Lexicon Pharmaceuticals, INC. | $13.52 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Panday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.